Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
Trial details
- Registry ID
- NCT07326566
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as BDTX-1535; TMZ; Temodar
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIIINCT07326566 | BDTX | Phase 2 | Recruiting | 2028-11Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |